Nolvadex Patent Life Allows Firm To Benefit From Prevention Claim - Zeneca
Executive Summary
Zeneca will be able to reap the benefits from a breast cancer prevention indication for its flagship oncologic agent Nolvadex (tamoxifen) before its U.S. patent runs out in 2002, CEO David Barnes said at a press conference in London Aug. 6.